Radiopharm Theranostics Executed A Subscription Agreement For A Private Placement Of Ordinary Shares To Lantheus Holdings Inc., Raising $5M

• Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 million
• Placement at A$0.060 per share, representing a premium of 150% to the last closing price of A$0.024
• Lantheus shareholding in Radiopharm increases to 12.16% following the placement
• The funds raised will be applied to the development of Radiopharm's clinical pipeline

SYDNEY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it has executed a subscription agreement for a private placement of ordinary shares to Lantheus Holdings Inc. ( "Lantheus"), raising US$5.0 million (A$8.0 million).

The placement of 133 million shares was completed at an issue price of A$0.060 per share, representing a 150% premium to the last traded price of RAD shares (A$0.024). Settlement is expected to occur within 7 days.

The placement replaces 6-month options that the Company issued in August 2024 (see ASX announcement 20 June 2024).